📄 AEON BIOPHARMA, INC.

AEON Biopharma, Inc. is a clinical stage biopharmaceutical company focused on developing a botulinum toxin complex, ABP-450, for debilitating medical conditions. The company plans to seek regulatory approval of ABP-450 as a biosimilar product in the United States, targeting the therapeutic botulinum toxin market. AEON has exclusive development and distribution rights for certain therapeutic uses of ABP-450 in the United States, Canada, the European Union, the United Kingdom, and certain other international territories. Key risk: The pharmaceutical industry is highly competitive, and many competitors have greater resources, which may render AEON's technologies or products obsolete or uneconomical. Proceeds: General corporate and working capital purposes

AEON Biopharma, Inc. is a clinical stage biopharmaceutical company focused on developing a botulinum toxin complex, ABP-450, for debilitating medical conditions. The company plans to seek regulatory approval of ABP-450 as a biosimilar product in the United States, targeting the therapeutic botulinum toxin market. AEON has exclusive development and distribution rights for certain therapeutic uses of ABP-450 in the United States, Canada, the European Union, the United Kingdom, and certain other international territories.